Friday , November 17 2017
Home / Precision Medicine

Precision Medicine

Researchers Identify Potential Therapeutic Target in Aggressive Breast Cancer Cells

ORCHARD PARK, N.Y., Nov. 15, 2017 /PRNewswire/ — An especially aggressive breast cancer cell can respond to hormone therapy if they express a specific protein known as estrogen receptor beta (ERβ), according to new research published on the cover of Oncotarget. The findings also revealed additional molecules that the researchers …

Read More »

Blueprint’s BLU-285 Shows Strengthened Clinical Activity across Spectrum of KIT and PDGFRα Genotypes in Early-Stage GIST Study

CAMBRIDGE, Mass., Nov. 10, 2017 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new Phase 1 clinical data for BLU-285, a potent and highly selective KIT and PDGFRα inhibitor in development as a potential …

Read More »

Opdivo and Yervoy Combo Increased Overall Survival Across PD-L1 Expression Levels in Advanced RCC

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced today results from a new exploratory analysis of the phase 3 CheckMate -214 trial evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus the standard of care, sunitinib, in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma (RCC). In an exploratory analysis of PD-L1 expression …

Read More »

GeneCentric Presents Data on Potential of its Cancer Subtyping Platform to Identify Responders to PARP Inhibitors for NSCLC

DURHAM, N.C.–(BUSINESS WIRE)–GeneCentric Therapeutics announced today that it will present data on the potential of non-small cell lung cancer (NSCLC) biologic subtypes based on its Cancer Subtyping Platform (CSP®) to provide novel biomarkers for response to PARP inhibitors. The data will be presented at a poster session during the 2017 …

Read More »

NIH Partners with 11 Drug Companies to Launch PACT as Part of Cancer Moonshot Project

The National Institutes of Health and 11 leading biopharmaceutical companies today launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot.  PACT will initially focus on efforts to identify, develop and validate robust biomarkers — standardized biological markers …

Read More »

Researchers Identify Genetic Drivers of Most Common Form of Lymphoma

DURHAM, N.C. — Lymphoma is the most common blood cancer, but the diagnosis belies a wildly diverse and little understood genetic foundation for the disease that hampers successful treatment. An international research effort led by Duke Cancer Institute scientists has been working to better understand the genetic underpinnings of the …

Read More »

Syros Presents Biomarker Data from its Mid-Stage Trial in Genomically Defined AML and MDS Patients

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, today announced that the biomarker status of patients screened for the ongoing Phase 2 clinical trial of SY-1425, its first-in-class selective retinoic acid receptor alpha (RARα) agonist, in …

Read More »

Drug Combo Gangs up to Take on Triple-Negative Breast Cancer

ANN ARBOR, Michigan — In the hunt for novel treatments against an aggressive form of breast cancer, researchers combined a new protein inhibitor with a chemotherapy drug to create a powerful combination that resulted in cancer cell death. Triple-negative breast cancer is a subtype that does not express hormone receptor …

Read More »

Roche, Foundation Medicine Blood Test Could Help Personalize Cancer Immunotherapy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. (NASDAQ:FMI) today announced presentations at the European Society for Medical Oncology (ESMO) Annual Meeting highlighting validation data for its novel assay to measure tumor mutational burden from blood (bTMB). These presentations will highlight retrospective data analysis from Roche/Genentech’s Phase II POPLAR and Phase III OAK studies …

Read More »

New Approach to Genetic Testing Leads to Dramatic Response in MET Fusion Lung Cancer

There are many ways a gene can be altered and there are many genes that, when altered, can cause cancer. Testing individually for each possible alteration in every cancer-related gene is not feasible as it would require hundreds of individual tests and many, many thousands of dollars. A University of …

Read More »